NCT Number: NCT06386198
The Health Advocate for Liver Transplant (HEAL-Tx) Transition of Care Pilot is a nonrandomized, open-label intervention pilot of a health advocate intervention aimed to assess feasibility and acceptability of integrating a Health Advocate onto the transplant team to help adolescents transition their care to adult transplant teams. Across studies, health advocate roles vary, and can include coordinating medical care treatment, facilitating financial assistance (e.g., taxi vouchers), and connecting patients to community resources, which can improve self-management, mitigate social risks, and lead to better communication between the healthcare system and the family. In this pilot, the investigators will adapt this intervention for adolescent/young adult liver transplant patients and measure acceptability and feasibility according to RE-AIM.
Interested in participating?
Request Info18 year–25 year
All sexes
Interventional
Not applicable
University of California San Francisco, San Francisco, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Health Advocate intervention will include helping pediatric liver transplant recipients and their families address unmet household social needs (e.g., food insecurity), improve patient-provider communication, and enhance care coordination.
Other names: Patient Navigator
Time frame: Baseline and 180 days
The investigators will administer a survey of patient experience at study enrollment and at the end of the intervention to assess for changes in patient experience with the transplant team. These questions will focus on experiences receiving transplant care, experiences discussing social needs with the transplant team, and overall subjective assessment of the transplant recipient's overall health.
Time frame: Baseline and 180 days
Medication level variability index (MLVI) defined as the standard deviation of at least 3 outpatient tacrolimus trough levels (binary >/=2.0 or <2.0). The investigators will assess this at study entry and again at 180 days.
Time frame: 180 days
The Health Advocate will keep a detailed journal entry after each encounter and certain Health Advocate interactions will be recorded. The investigators will qualitatively analyze these journal entries and recordings to identify what functions the health advocate undertook.
Time frame: 180 days
The investigators will conduct in-depth interviews with the patient participant and clinical team members to assess overall satisfaction with the intervention.
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Acronym: HEAL-Tx:ToC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05700799
Hematologic Diseases, Hemic and Lymphatic Diseases
San Francisco, California, United States
View Trial DetailsNCT04477967
Digestive System Diseases, Hematologic Diseases
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT05818644
Hematologic Diseases, Hemic and Lymphatic Diseases
Groningen, Netherlands
View Trial DetailsNCT07715500
Chronic Liver Disease and Cirrhosis, Donor Hepatectomy
New Delhi, India
View Trial Details